Dr. Geoffrey Eubank, M.D., Medical Director of the Mid Ohio MS Center at OhioHealth Neurological Physicians, discusses 2 Phase lll clinical trials of Enspryng™ (satralizumab-mwge) that demonstrated robust efficacy and safety profiles for the treatment of adults living with anti-aquaporin-4 (AQP4) antibody-positive NMOSD, a rare disabling neurological disorder often misdiagnosed as multiple sclerosis. Enspryng represents significant therapeutic progress for the NMOSD community, offering the only FDA-approved injectable treatment option that can be self-administered every four weeks by a person living with NMOSD or a caregiver following training from a healthcare provider.
Geoffrey A. Eubank, MD, ABPN, is an accomplished neurologist who specializes in electromyography and other electrodiagnostics, stroke, multiple sclerosis and epilepsy.
Dr. Eubank is currently Medical Director of the Mid Ohio MS Center at OhioHealth Neurological Physicians, formerly Neurological Associates, and is the Stroke Clinical Services Advisor of Riverside Methodist’s Comprehensive Stroke Center.
He is on the medical staff at OhioHealth Riverside Methodist Hospital in Columbus, where he is stroke coordinator. Active as a volunteer physician for free clinics and for the National Multiple Sclerosis Society, Dr. Eubank has published research in several areas and is a member of several medical societies. He is also involved with research in multiple sclerosis and stroke.
A native of Pompton Plains, NJ, Dr. Eubank attended Pennsylvania State University and graduated from Muskingum College majoring in chemistry and mathematics. He obtained his medical doctor degree from The Ohio State University. He completed his preliminary medicine internship at Riverside Methodist Hospital and his neurology residency at the Cleveland Clinic Foundation, where he was chief neurology resident.
Dr. Eubank was certified by the American Board of Psychiatry and Neurology in 1996
Medical Director of the Mid Ohio MS Center at OhioHealth Neurological Physicians.